An age-old natural healing modality, it has been proven in a number of clinical trials to support the immune system and improve patient outcomes.
- Active Clinical Trials
In Europe, where it's approved for cancer care in some countries and more commonly used, it can be taken intravenously or in pill form.
And though not approved by the FDA in the United States, there are U.S. based integrative oncologists that do offer it as a treatment.
None currently available
Title: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe
Summary: This randomized study compared the outcomes for patients receiving Mistletoe Therapy and the standard treatment of care versus those just receiving the standard treatment of care.
- Those receiving the treatment took twice as long to show sign of disease recurrence
- The survival rate for those receiving treatment was twice as long as well
Title: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients
Summary: This randomized study provided patients either Mistletoe Therapy plus the standard of care or just the standard of care.
- Those taking the mistletoe therapy saw a dramatic increase in the white blood cells of the immune system
- Patients on the mistletoe therapy saw an improved quality of life
Title: Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice
Summary: This study tested the effects of Mistletoe Therapy in conjunction with chemotherapy and radiation and found they worked synergistically to prolong the survival time in mice with gliomas.
- Mistletoe Therapy led to an increase in the number of immune cells in the mice
- The authors conclude, “adjuvant mistletoe therapy should be considered as an auspicious treatment option for glioma patients.”